RNA5S17: A promising drug target and biomarker for cancer (G100169768)

Target Name: RNA5S17

NCBI ID: G100169768

RNA5S17

Other Name(s): RN5S17 | 5S rRNA 17 | RNA, 5S ribosomal 17

RNA5S17: A promising drug target and biomarker for cancer

RNA5S17 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for cancer. Its unique structure and expression pattern make it an attractive target for drug developers due to its potential to modulate gene expression and contribute to the development of cancer.

Structure and Expression

RNA5S17 is a small RNA molecule that consists of 17 nucleotides. It has a characteristic stem-loop structure that is commonly found in non-coding RNAs. The stem loop is responsible for the stability and translation of RNA molecules. RNA5S17 has a unique feature at its 3' end, a double-stranded RNA domain that is composed of four contiguous nucleotides.

RNA5S17 is expressed in various tissues and cells, including human cancer cells. Its expression level is highly dependent on the cell type and the developmental stage of the organism. RNA5S17 has been shown to be involved in cell signaling pathways, including the regulation of cell adhesion, migration, and invasion.

Drug Target Potential

RNA5S17 is a promising drug target due to its unique structure and expression pattern. The double-stranded RNA domain and the stem loop are potential sites for drug intervention. Drugs that can modulate the activity of RNA5S17 can be developed to treat various types of cancer, including breast, ovarian, and colorectal cancers.

One potential drug that can target RNA5S17 is small molecule inhibitors. These drugs work by binding to specific RNA5S17 molecules and modulating their activity. Small molecule inhibitors have been shown to be effective in preclinical studies for treating cancer. RNA5S17 has also been shown to be a potential biomarker for cancer, which can be used to monitor the effectiveness of anti-cancer drugs.

Biomarker Potential

RNA5S17 has been shown to be involved in various cellular processes that are important for cancer development. Its expression level is highly dependent on the cell type and the developmental stage of the organism. This makes RNA5S17 an attractive biomarker for cancer diagnosis and monitoring.

RNA5S17 has been shown to be involved in cell signaling pathways that are important for cancer growth and progression. One of these pathways is the regulation of angiogenesis, which is the process by which new blood vessels are formed to supply oxygen and nutrients to cancer cells. RNA5S17 has been shown to be involved in the regulation of angiogenesis, which can be a potential target for anti-cancer drugs.

Another pathway that RNA5S17 is involved in is the regulation of cell adhesion. Cancer cells have a high degree of cell adhesion, which allows them to migrate and invade surrounding tissues. RNA5S17 has been shown to be involved in the regulation of cell adhesion, which can be a potential target for anti-cancer drugs.

Conclusion

RNA5S17 is a promising drug target and biomarker for cancer. Its unique structure and expression pattern make it an attractive target for drug developers. The double-stranded RNA domain and the stem loop are potential sites for drug intervention, and RNA5S17 has been shown to be involved in various cellular processes that are important for cancer growth and progression.

RNA5S17 has the potential to be developed into a new drug or a biomarker for cancer diagnosis and monitoring. Further studies are needed to fully understand its role in cancer biology and develop effective drugs or biomarkers based on it.

Protein Name: RNA, 5S Ribosomal 17

The "RNA5S17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNA5S17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets